摘要 |
Disclosed is an accelerated progression relapse test for use in the prognosis of disease states. According to the test disclosed herein, it can be determined whether a patient would benefit from treatment for a disease state or whether the patient's prognosis would not have a high probability of benefit with additional treatment. In particular, the test is useful in determining a patient's prognosis for cancer (breast, colon, lung, etc). For example, the test of the invention can be used to determine the prognosis for estrogen receptor positive (ER+) breast cancer patients. In the test for ER+ breast cancer patients, four genetic probes are employed that target MK167, CDC6, and SPAG5 gene products. The ER+ breast cancer test stratifies a patient population into two groups, with the low gene expression group identifying a group that is less likely to benefit from additional treatment measures, and a high gene expression group, identifying a group more likely to benefit from additional treatment measures. |